← Back to headlines
Neurocrine to Acquire Soleno for Drug Targeting Relentless Hunger Disorder
Neurocrine Biosciences announced its intent to acquire Soleno Therapeutics, a move that will secure a drug designed to treat a relentless hunger disorder, expanding Neurocrine's therapeutic portfolio.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Philippines Announces Results of April 2026 Physicians Licensure Examination
just now
Pagasa flags 2 areas for dangerous heat index levels on April 9
just now
Philippines Experiences High Heat Index, DOH Issues Warnings as Areas Log Danger Levels
just now
Laguna Province Opens First Free Chemotherapy Center
just now